FA
EBS icon

Friess Associates’s Emergent Biosolutions EBS Stock Holding History

Friess Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-255,443
Closed -$12.9M – 123
2019
Q1 		$12.9M Sell
255,443
-1,502
-0.6% -$88.6K 0.95% 53
2018
Q4 		$15.2M Buy
+256,945
New +$16.6M 1.3% 38

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Friess Associates's EBS Position: Q2 2019 in Review

Friess Associates sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 255,443 shares — an estimated $12.9M sold.

Friess Associates first reported a position in EBS in Q4 2018 and held it in 2 quarters. The position peaked at $15.2M in Q4 2018. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

  • Friess Associates reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
  • Friess Associates sold 255,443 Emergent Biosolutions shares in Q2 2019, an estimated $12.9M.
  • Friess Associates first reported a position in Emergent Biosolutions in Q4 2018 and held it in 2 quarters.
  • Friess Associates's Emergent Biosolutions position peaked at $15.2M in Q4 2018.
  • 233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Friess Associates's 13F filing for Q2 2019, filed 14 Aug 2019.